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Background: Although uncomplicated cystitis is often self-limiting, most such patients will be prescribed antibiotic
treatment. We are investigating whether treatment of cystitis with an NSAID is as effective as an antibiotic in
achieving symptomatic resolution.
Methods/Design: This is a randomized, controlled, double blind trial following the principles of Good Clinical
Practice. Women between the ages of 18 to 60 presenting with symptoms of uncomplicated cystitis are screened
for eligibility. 500 women from four sites in Norway, Sweden and Denmark are allocated to treatment with 600 mg
ibuprofen three times a day or 200 mg mecillinam three times a day for three days. Allocation is conducted using
block randomization. The primary outcome is the number of patients who feel cured by day four as recorded in a
diary. Adverse events will be handled and reported in accordance with Good Clinical Practice.
Discussion: If treatment of uncomplicated cystitis with ibuprofen is as effective as mecillinam for symptom relief,
we can potentially reduce the use of antibiotics on a global scale.
Trial registration: EudraCTnr: 2012-002776-14. ClinicalTrials.gov: NCT01849926.
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Uncomplicated cystitis accounts for 3–4% of all consul-
tations in General Practice and is the most common
bacterial infection in women [1,2]. Half of all women
will go through an uncomplicated cystitis during life [3].
Of all these women, 20% will experience recurring infec-
tions [4].
Research has shown that if a patient experiences dys-
uria and pollaksiuria and/or urinary urgency and/or
macroscopic hematuria and the symptoms have lasted
less than seven days, it is very likely that she has cystitis.
If she furthermore has no vaginal symptoms such as dis-
charge or irritation, the likelihood increases to 90% [5].* Correspondence: ingvild.vik@medisin.uio.no
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unless otherwise stated.Hence, it is found that uncomplicated cystitis can be di-
agnosed and treatment can be prescribed over the tele-
phone [6].
A few trials have been conducted comparing the treat-
ment of uncomplicated cystitis with antibiotics versus
placebo. The results showed that the symptomatic im-
provement and bacteriological cure were significantly
delayed in the placebo group, but at the same time the
placebo group showed a symptomatic improvement rate
of around 50% after three days. In these trials it seemed
that most episodes of uncomplicated cystitis were self-
limiting and that the patients became symptom free
within a week [7-9].
In Norway the national guidelines for antibiotic use in
primary care recommend a three-day treatment with an
antibiotic for uncomplicated cystitis. Mecillinam, nitro-
furantoin and trimethoprim are listed as first choices
[10]. Previous epidemiological investigations of women
with symptoms of cystitis in a general practice populationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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bacterial agent (70-80%) and secondly Staphylococcus
saprophyticus (S.saprophyticus) (10-15%) [11-14]. Retro-
spective studies have found an increase in bacterial resist-
ance to quinolones, cephalosporins and trimethoprim.
Mecillinam and nitrofurantoin still show relatively low
levels of resistance to E.coli [15].
A pilot study comparing the treatment of uncompli-
cated cystitis with ciprofloxacin to ibuprofen was re-
cently published. The study included 69 patients and it
showed that 58% of the patients who received ibuprofen
and 52% of the patients who received ciprofloxacin were
asymptomatic after four days. Urine cultures taken on
day seven showed more negative cultures among the pa-
tients who had received ciprofloxacin (72% vs. 49%), but
the difference was not statistically significant [16].
There is an ongoing trial in Germany evaluating whether
the use of antibiotics for uncomplicated urinary tract in-
fection (UTI) can be reduced by giving initial treatment
with ibuprofen [17].
On a global level antibiotic consumption is on the rise.
The rise of consumption and the increase in use of last-
resort antibiotic drugs raises serious concerns for public
health. Programs that promote rational use through co-
ordinated efforts by the international community should
be a priority [18]. The use of cephalosporins, quinolones
and long-term use of antibiotics have been identified as
risk-factors for infections caused by extended-spectrum-
beta-lactamase producing (ESBL) E. coli and Klebsiella
species (Klebsiella spp.) [19].
In the US and southern Europe ciprofloxacin has been
used as a first choice for treating many infections, in-
cluding uncomplicated cystitis [20].
The aim of the study is to evaluate ibuprofen versus
mecillinam in the treatment of uncomplicated cystitis in
healthy, adult, non-pregnant women. Our hypothesis is
that symptomatic treatment with NSAIDs is not inferior
to antibiotic treatment in this group, and that ibuprofen
does not give more complications than mecillinam. An-
other unanswered question is whether ibuprofen might
have an antimicrobial effect.
Methods
Design
This is a double blind randomized controlled trial
(RCT). Half of the patients will receive treatment with
mecillinam and the other half will receive treatment with




The research project is a co-work between research fa-
cilities in Norway, Sweden and Denmark. The study willbe recruiting patients from two Accident and Emergency
Out Patient Clinics in Norway and general practices in
Sweden and Denmark.
Inclusion and exclusion criteria
Patients presenting with symptoms of an uncomplicated
cystitis will be screened for eligibility using a question-
naire. Such a questionnaire is already in use at the Acci-
dent and Emergency Out Patient Clinic in Oslo and we
intend to use the same questionnaire at all inclusion
sites. The screening will be carried out by a trained study
nurse or doctor.
The patients who are eligible will be given information
about the study, both orally and in writing. If they decide
to participate, they will be given a consent form which
will be signed both by the patient and the study nurse or
doctor. The consent form is made in accordance with
the guidelines of the Regional Committee for Medical
and Health Research Ethics in Norway (REK).
Inclusion criteria:
 woman between 18 and 60 years of age
 dysuria and pollakisuria and/or urinary urgency
 ability to give written consent
Exclusion criteria:
 pregnancy or breastfeeding child under one month
of age
 diabetes, heart insufficiency, kidney disease or
genetic aciduria
 clinical suspicion of pyelonephritis; fever, reduced
general condition, upper back pain
 vaginal symptoms such as discharge or irritation
 severe abdominal pain
 symptoms that have lasted for more than seven days
 one or more urinary tract infections within the lasts
four weeks
 permanent bladder catheter or use of bladder
catheter within the last four weeks
 use of antibiotics within the last two weeks
 participation in a clinical trial within the last four weeks
 previously undergone a pyelonephritis
 previous allergic reaction to penicillin
 previous allergic reaction to ibuprofen, or worsening
of asthma when using NSAIDs
 narrow oesophagus
 use of the drug probenecid
 severe gastritis or previous ulcer, Crohn's disease or
Ulcerative colitis
 ongoing use of NSAIDs, steroids, anticoagulative
treatment or use of immunosuppressant drugs
 thrombocytopenia
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addiction
 unable to communicate in Norwegian, Swedish or
Danish language respectivelyData collection and management
Urine samples
Urine cultures are obtained on day one and after two
weeks.Symptom score
The patients are given a diary where they daily will
register symptom load, possible complications or adverse
effects and on which day they feel completely cured. The
diary is based on a previously validated version [21]. We
will contact the patients after two weeks to make sure
they have followed the study procedures. After four
weeks we will perform a final telephonic follow up.Outcomes
Main outcome measures
Proportion of patients who felt cured by day four as reg-
istered in the patient diary.Secondary outcome measures
The patients' symptom load with regard to specific
symptoms as registered in the diary.
Proportion of patients who had a relapse of symptoms
within four weeks after being included in the study.
Proportion of patients who were in need of a secondary
medical consultation within the study period.
Proportion of patients who developed an upper urinary
tract infection (pyelonephritis).
Proportion of patients who experienced adverse effects
and severe adverse effects.
Proportion of patients with a positive urine culture after
two weeks.
Evaluation of the use/continued use of the questionnaire
in diagnosing uncomplicated cystitis.Does ibuprofen have an antimicrobial effect?
As a sub study it would be of interest to investigate
whether ibuprofen has an antimicrobial effect. To do
this, it will first be necessary to develop a new test series
in the bacteriological laboratory. It is necessary to test
breaking points for the antimicrobial effect of ibuprofen
in urine samples inoculated with some of the most com-
mon urine bacteria such as E. coli, Klebsiella spp., S.
saprophyticus and Enterococcus spp..
The details of such a study will be described in a par-
ticular protocol at a later stage.Sample size
We assume that 85% in the mecillinam group will feel
completely cured after four days and consider a 10% ab-
solute reduction to 75% in the ibuprofen group as a
maximum relevant difference when holding that ibupro-
fen is non inferior to mecillinam. With alpha 0.05 and 1-
beta of 80% we estimate that we need about 150 patients
in each group. To add up for drop outs and withdrawals
we aim at recruiting 250 in each group. Stratification is
not found to be necessary. We considered whether or
not we should expect a cluster effect in the study. We
concluded that the cluster effect is negligible as all patients
are recruited with the same inclusion and exclusion cri-
teria and randomization is made on the patient level. 85%
is based on an ongoing study on uncomplicated cystitis at
the Accident and Emergency Out Patient Clinic in Oslo
where 85% of patients felt cured after four days. (Marianne
Bollestad, personal communication).
Blinding and randomization
Production of the study medicine
The study is double blind. We are buying the original
tablets directly from the manufacturers in the pharma-
ceutical industry, Ibuprofen ratiopharm (ibuprofen)
600 mg from Ratiopharm and Selexid (mecillinam)
200 mg from Leo Pharma. Kragerø Tablettproduksjon AS,
a company in Kragerø, Norway, will over-encapsulate the
medicine to be used in this study. The original tablets will
be put in a gelatine capsule. The capsules will then be
filled with small balls of sugar so that the capsules become
as similar as possible. The capsule consists of two parts
which will be put together and firmly tightened to make it
as difficult as possible to open. We have already looked at
the final product and this procedure will give the capsules
the same look, feel, weight and taste.
The study medicine is packed in two different kits, one
with 9 capsules containing one tablet of mecillinam each,
the other with 9 capsules containing one tablet of ibupro-
fen each. Each kit is then labelled with a study number.
This labelling is done following a randomization list made
by a statistician using block randomization.
At inclusion the patient receives a kit labelled only with
the study number. Neither the research nurse or doctor
nor the patient will know what active substance is given,
thus resulting in double blinding for both nurse/doctor
and patient. A list linking the study number to the active
substance is kept at Kragerø Tablettproduksjon AS. The
list will be retrieved only at the end of the study when all
the data has been collected and entered into the statistical
program and all analysis are completed.
Handling of the study medicine
The study medicine is packed and labelled at Kragerø
Tablettproduksjon AS. They will send the study medicine
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list. At each study site the study medicine will be handled
according to existing local routines and guidelines.
Intervention
Day 1
A nurse or doctor fills out the questionnaire together
with the patient. The questionnaire will give us informa-
tion about symptom load at inclusion. The patient and
nurse or doctor sign the consent form.
The patients are randomized into two groups. Both
groups receive active treatment and none are given pla-
cebo. One group will be given mecillinam 200 mg TID
for three days and the other will be given ibuprofen
600 mg 3 TID for three days.
The nurse will take a urine dipstick (leukocytes, nitrite
and blood) and register the result in the questionnaire.
A urine culture will be sent to the laboratory and the pa-
tients will receive equipment to take a new urine sample
at home and send it to the laboratory for a second cul-
ture after two weeks.
Day 1–7
The patients receive a diary where they are going to regis-
ter the severity of symptoms on a daily basis and on which
day they feel completely cured. They will also register pos-
sible adverse effects or complications and whether they
finished the three day treatment with study medicine or
not. If they didn't finish the treatment we will ask how
many capsules they have left. When the patients have
completed the diary they will send it to the study site.
Day 14
The patient will provide a second urine sample for a
control urine culture. A study nurse or doctor will call
the patients after two weeks for a follow up interview. If
they have not yet sent us the diary or delivered a second
urine culture, they will be reminded to do so.
Day 28
A study nurse or doctor will perform a short telephonic
interview with questions about possible relapse of symp-
toms and need for additional treatment.
The patients will be instructed only to use paracetamol
if they have the need for additional pain relief. They are
not allowed to take any NSAIDs during the study period
as this can interfere with our measurements. If we find
they have been taking additional NSAIDs during the
study period this will lead to exclusion from the study.
If a patient contacts us having decided to quit the
study because she wants to be sure she is given anti-
biotic treatment, she will be given mecillinam for three
days. These patients will be included in the study ac-
cording to the principle of intention to treat (ITT).Safety
Criteria for termination of the study
For the individual patient
– developing an upper UTI in need of hospitalization
– serious adverse effect or allergic reaction to the
study medicine
– a wish to withdraw from the study
For the study itself
– when the sufficient number of patients have been
included
– if more than ten patients within the first 100
patients included are in need of hospitalization, this
will be a cause for unblinding of these patients. This
is to see whether there are significantly more
patients in the ibuprofen group who were in need of
hospitalization, and if so we will have to consider
terminating the study.
Adverse effects
We expect some gastrointestinal adverse effects for both
treatments. All adverse effects will be registered in the
diary. If the patient should experience an allergic reac-
tion, a severe adverse effect or signs of developing an
upper UTI, she is instructed to contact the study centre
or the local emergency unit immediately. These condi-
tions demand a change of active treatment and may be a
cause to reveal the active substance this patient has been
given. A box containing a sealed envelope for each study
number will be kept at each study centre. Each envelope,
marked only with the study number, contains a note
with the name of the active substance given to this pa-
tient. If unblinding is necessary, the envelop for this
study number will be opened and the patient and the
doctor treating the patient will be informed of what
active substance the patient has received. The doctor re-
sponsible for the study will not be informed and will stay
blinded.
When registering the data from the study the adverse
effects will be divided into three groups, adverse events
(AE), serious adverse events (SAE) and suspected unex-
pected serious adverse reactions (SUSAR). These will be
reported from each study site to the Sponsor using re-
port forms standardized by the Oslo University Hospital
according to the principles of GCP.
Detailed information will be sent to the authorities in
accordance with Regulations on clinical trials of pharma-
ceuticals in humans.
Insurance
A collective insurance will be taken out through the
Norwegian drug liability insurance for all participants in
the study. The participants are also insured through the
national health service system.
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An investigators study file (ISF) is established at each of
the study sites. The ISF will contain all the essential in-
formation about the study. A trial master file (TMF) is
established in Oslo by the national coordinating investi-
gator. The registering of data will be made consecutively
throughout the study period. The data will be registered
in a case report form (CRF) for each patient according
to the principles of GCP. The handling of the data will
follow the principles of GCP. The data will be kept in a
locked facility for 15 years after the study is finished.
After this it will be destroyed.
Statistical analysis
Data will be registered and analysed in statistics program
SPSS version 22. We will do descriptive analysis and lo-
gistic regression analysis.
Monitoring
A monitor has been appointed in each country. The
study will be carried out according to the principles of
GCP, the latest revision of the Declaration of Helsinki
and national laws and regulations.
Ethical considerations
Uncomplicated cystitis is predominantly a self-limiting
condition and the need for antibiotic treatment of this
condition is controversial. However, the condition is
often painful and the patients feel the need to take pain
medication, often NSAIDs.
In this study half of the patients will receive an anti-
biotic (mecillinam) and the other half will receive an
NSAID (ibuprofen), they will also have the opportunity
to take paracetamol in addition to the study medicine,
so no one should suffer unnecessary pain.
The risk of developing a more serious infection despite
not receiving antibiotic treatment is considered to be
small. The pilot study in Germany showed that 33.3% of
the patients in the NSAID group and 18.2% in the anti-
biotic group required secondary antibiotic treatment. The
difference was notable, but not statistically significant.
None of the patients were in need of hospitalization. No
patients experienced severe adverse effects [15].
If the patient qualifies for inclusion in the study she
will receive information both orally and in writing. It will
be pointed out that participation is completely voluntary
and that declining does not affect the kind of help or
treatment she will receive. It will be made clear to the
patient that she can choose to quit the study at any time.
If the patient has any questions regarding the study she
can contact a research nurse or a research doctor at the
study site. The phone numbers are listed in the consent
form received and signed at inclusion.It will be emphasized that if the patient gets worse
during the study treatment or experiences any severe ad-
verse effects, she must contact the study site or come
back for a medical consultation. Preferably at the site of
inclusion, otherwise at the local emergency unit or other
institution with a special agreement with the local study
site. Information about such institutions will be made
very clear, both orally and in the consent form.
The protocol has been approved by the Norwegian
Medicines Agency (NoMA) and by the Regional Com-
mittee for Medical and Health Research Ethics. The
protocol has also been approved by the corresponding
authorities in Sweden and Denmark with minor local
adjustments.
Discussion
As uncomplicated cystitis is the most common bacterial
infection in adult women, this represents a large portion
of the consultations at a general practice. If we could re-
duce the need for antibiotic treatment for this condition,
and maybe find that it can be treated with a simple over-
the-counter drug such as ibuprofen, this will reduce the
number of consultations and the total use of antibiotics.
A double blind RCT ensures reproducibility of the re-
sults. In accordance with national guidelines for diagno-
sis and management of acute uncomplicated UTIs,
inclusion was not determined by bacteriologically veri-
fied UTI, but by typical symptoms [22].
Bacteriological samples are secured at the time of
inclusion, in the case of treatment failure and after
finishing treatment. This allows for analysis of relation
between treatment failure and bacteriological findings,
as well as allowing for a sub study of antimicrobial ef-
fect of ibuprofen.
If we demonstrate that the proportion of patients with
persistent bacteriuria is equal in the two groups, this will
show that the immune system of the women in the ibu-
profen group may have handled the bacteria without an-
tibiotics, or that ibuprofen may have an antimicrobial
effect.
If we find that and NSAID is equally effective as an
antibiotic, this may contribute to a reduction in the use
of antibiotics and reduce antibiotic resistance globally.
This is beneficial to the environment and will reduce the
costs in health services internationally.
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